Managers / Q4 2022 · view latest →
Altium Capital Management LLC
CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711
Reported Value
$197M
Q4 2022
Positions
94
Filings on Record
25
2019–present window
Filed
Feb 14, 2023
original filing
Summary
Altium Capital Management LLC reported $197M in U.S.-listed holdings across 94 positions for Q4 2022.
Its largest position, Astria Therapeutics, represents 10.3% of the portfolio.
Compared with Q3 2022, the fund opened 27 new positions and exited 67.
Portfolio Metrics
Turnover
+30.5%
vs prior filed quarter
Top-10 Concentration
+44.5%
share of reported value
Largest Position
+10.3%
Astria Therapeutics
New / Exited
27 / 67
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 81.2% · $160M
- Other · 15.2% · $30M
- ADR · 3.1% · $6M
- Equity WRT · 0.5% · $919,942
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| REPLREPLIMUNE GROUP INC | NEW | +160.0K | 160.0K | +$4M | $4M |
| TNDMTANDEM DIABETES CARE INC | NEW | +90.0K | 90.0K | +$4M | $4M |
| OUTLOOK THERAPEUTICS INC | NEW | +3.33M | 3.33M | +$4M | $4M |
| PACBPACIFIC BIOSCIENCES CALIF IN | NEW | +365.0K | 365.0K | +$3M | $3M |
| BHVNBIOHAVEN LTD | NEW | +200.0K | 200.0K | +$3M | $3M |
| NEONEOGENOMICS INC | NEW | +285.0K | 285.0K | +$3M | $3M |
| PCVXVAXCYTE INC | NEW | +43.0K | 43.0K | +$2M | $2M |
| SAGE THERAPEUTICS INC | NEW | +50.0K | 50.0K | +$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
84 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ASTRIA THERAPEUTICS INC | COM | 10.26% | $20M | 1.36M |
| 2 | ADMAADMA BIOLOGICS INChistory → | COM | 5.66% | $11M | 2.87M |
| 3 | CHINOOK THERAPEUTICS INC | COM | 5.13% | $10M | 385.0K |
| 4 | BLUBELLUS HEALTH INC NEWhistory → | COM NEW | 4.73% | $9M | 1.13M |
| 5 | PEPPERLIME HEALTH ACQUSTN CO | CLASS A ORD SHS · *W EXP 10/01/202 | 3.83% | $8M | 1.10M |
| 6 | AKROAKERO THERAPEUTICS INChistory → | COM | 3.48% | $7M | 125.0K |
| 7 | CYMABAY THERAPEUTICS INC | COM | 3.27% | $6M | 1.02M |
| 8 | VRNAVERONA PHARMA PLChistory → | SPONSORED ADS | 2.85% | $6M | 215.0K |
| 9 | INTRA-CELLULAR THERAPIES INC | COM | 2.69% | $5M | 100.0K |
| 10 | AMLXAMYLYX PHARMACEUTICALS INChistory → | COM | 2.63% | $5M | 140.0K |
| 11 | RYTMRHYTHM PHARMACEUTICALS INChistory → | COM | 2.52% | $5M | 170.0K |
| 12 | ARCELLX INC | COMMON STOCK | 2.36% | $5M | 150.0K |
| 13 | REPLREPLIMUNE GROUP INChistory → | COM | 2.21% | $4M | 160.0K |
| 14 | KARUNA THERAPEUTICS INC | COM | 2.20% | $4M | 22.0K |
| 15 | XTNTXTANT MED HLDGS INChistory → | COM NEW | 2.10% | $4M | 6.25M |
| 16 | IVERIC BIO INC | COM | 2.07% | $4M | 190.0K |
| 17 | TNDMTANDEM DIABETES CARE INChistory → | COM NEW | 2.06% | $4M | 90.0K |
| 18 | GKOSGLAUKOS CORPhistory → | COM | 2.02% | $4M | 91.0K |
| 19 | ESPRESPERION THERAPEUTICS INC NEhistory → | COM | 1.96% | $4M | 620.0K |
| 20 | OUTLOOK THERAPEUTICS INC | COM NEW | 1.83% | $4M | 3.33M |
| 21 | RMDRESMED INChistory → | COM | 1.80% | $4M | 17.0K |
| 22 | AKOYA BIOSCIENCES INC | COM | 1.60% | $3M | 330.0K |
| 23 | QTRXQUANTERIX CORPhistory → | COM | 1.58% | $3M | 224.8K |
| 24 | MYGNMYRIAD GENETICS INChistory → | COM | 1.56% | $3M | 212.0K |
| 25 | KRMDKORU MEDICAL SYSTEMS INChistory → | COM | 1.55% | $3M | 855.0K |
| 26 | NEVRO CORP | COM | 1.53% | $3M | 76.0K |
| 27 | PACBPACIFIC BIOSCIENCES CALIF INhistory → | COM | 1.52% | $3M | 365.0K |
| 28 | BHVNBIOHAVEN LTDhistory → | COM | 1.41% | $3M | 200.0K |
| 29 | CTI BIOPHARMA CORP | COM | 1.37% | $3M | 450.0K |
| 30 | SIBNSI-BONE INChistory → | COM | 1.35% | $3M | 195.0K |
| 31 | NEONEOGENOMICS INChistory → | COM NEW | 1.34% | $3M | 285.0K |
| 32 | CARA THERAPEUTICS INC | COM | 1.07% | $2M | 196.0K |
| 33 | NBIXNEUROCRINE BIOSCIENCES INChistory → | COM | 1.06% | $2M | 17.5K |
| 34 | COLLCOLLEGIUM PHARMACEUTICAL INChistory → | COM | 1.06% | $2M | 90.0K |
| 35 | PCVXVAXCYTE INChistory → | COM | 1.05% | $2M | 43.0K |
| 36 | TG VENTURE ACQUISITION CORP | UNIT 08/15/2028 | 1.04% | $2M | 200.0K |
| 37 | PLRXPLIANT THERAPEUTICS INC | COM | 0.98% | $2M | 100.0K |
| 38 | SAGE THERAPEUTICS INC | COM | 0.97% | $2M | 50.0K |
| 39 | BIOLINERX LTD | SPONSORED ADS | 0.93% | $2M | 3.10M |
| 40 | AULT DISRUPTIVE TECHS CORP | COM | 0.78% | $2M | 150.0K |
| 41 | SYRSSYROS PHARMACEUTICALS INC | COM NEW | 0.57% | $1M | 315.1K |
| 42 | WESTERN ACQSTN VENTURES CORP | UNIT 09/01/2026 | 0.56% | $1M | 100.0K |
| 43 | POLISHED COM INC | COM · *W EXP 06/02/202 | 0.54% | $1M | 7.10M |
| 44 | MURPHY CANYON ACQUISITION CO | UNIT 01/25/2027 | 0.52% | $1M | 100.0K |
| 45 | ARYA SCIENCES ACQU CORP IV | CL A | 0.51% | $1M | 100.0K |
| 46 | COLISEUM ACQUISITION CORP | CLASS A ORD SHS · *W EXP 08/22/202 | 0.43% | $855,426 | 113.3K |
| 47 | TSHATAYSHA GENE THERAPIES INC | COM SHS | 0.41% | $811,455 | 359.1K |
| 48 | SOMALOGIC INC | CLASS A COM | 0.40% | $778,100 | 310.0K |
| 49 | HYREQHYRECAR INC | COM | 0.36% | $715,763 | 1.69M |
| 50 | TERNS PHARMACEUTICALS INC | COM | 0.36% | $712,600 | 70.0K |
| 51 | FAT BRANDS INC | *W EXP 07/16/202 | 0.35% | $683,270 | 227.0K |
| 52 | RXSTRXSIGHT INC | COM | 0.33% | $640,925 | 50.6K |
| 53 | PEPGPEPGEN INC | COM | 0.27% | $534,800 | 40.0K |
| 54 | GSR II METEORA ACQUISITN COR | UNIT 02/24/2027 | 0.27% | $528,500 | 50.0K |
| 55 | DDIDOUBLEDOWN INTERACTIVE CO LT | ADS | 0.26% | $514,402 | 60.9K |
| 56 | OPY ACQUISITION CORP I | COM CL A · *W EXP 09/22/202 | 0.26% | $504,225 | 100.0K |
| 57 | COLOMBIER ACQUISITION CORP | CL A · *W EXP 99/99/999 | 0.25% | $498,433 | 66.7K |
| 58 | MEDIWOUND LTD | SHS NEW | 0.19% | $368,088 | 27.3K |
| 59 | KURAKURA ONCOLOGY INC | COM | 0.18% | $349,937 | 28.2K |
| 60 | ABEOABEONA THERAPEUTICS INC | COM NEW | 0.17% | $334,784 | 108.7K |
| 61 | TROIKA MEDIA GROUP INC | COM | 0.16% | $310,026 | 2.67M |
| 62 | LIGHTNING EMOTORS INC | COM · *W EXP 05/18/202 | 0.12% | $238,553 | 1.23M |
| 63 | WEARABLE DEVICES LTD | *W EXP 09/14/202 | 0.09% | $171,086 | 1.41M |
| 64 | DIRECT DIGITAL HOLDINGS INC | *W EXP 02/15/202 | 0.07% | $140,400 | 180.0K |
| 65 | HEALTH SCIENCES ACQ CORP 2 | ORD SHS | 0.05% | $99,800 | 10.0K |
| 66 | JEFFS BRANDS LTD | *W EXP 08/26/202 | 0.04% | $79,327 | 480.8K |
| 67 | CINGWCINGULATE INC | *W EXP 12/10/202 | 0.03% | $64,827 | 270.0K |
| 68 | HARBOR CUSTOM DEVELOPMENT IN | *W EXP 10/07/202 · *W EXP 05/09/202 | 0.03% | $56,335 | 1.25M |
| 69 | ONFOWONFOLIO HOLDINGS INC | *W EXP 01/02/202 | 0.02% | $48,000 | 200.0K |
| 70 | NOCTURNE ACQUISITION CORP | RIGHT 12/26/2025 | 0.02% | $38,900 | 500.0K |
| 71 | NLS PHARMACEUTICS LTD | *W EXP 02/02/202 | 0.02% | $38,010 | 200.0K |
| 72 | NXGLWNEXGEL INC | *W EXP 12/01/202 | 0.02% | $33,750 | 225.0K |
| 73 | BNCWWCEA INDUSTRIES INC | *W EXP 02/11/202 | 0.01% | $22,500 | 250.0K |
| 74 | CHAVANT CAPITAL ACQUISITN CO | *W EXP 99/99/999 | 0.01% | $21,705 | 150.0K |
| 75 | NEXALIN TECHNOLOGY INC | *W EXP 09/15/202 | 0.01% | $21,000 | 105.0K |
| 76 | BRSWFBRUUSH ORAL CARE INC | *W EXP 08/03/202 | 0.01% | $19,543 | 360.6K |
| 77 | LUCYWINNOVATIVE EYEWEAR INC | *W EXP 08/16/202 | 0.01% | $18,345 | 150.0K |
| 78 | DIGITAL HEALTH ACQUISITION C | *W EXP 11/02/202 | 0.01% | $14,835 | 150.0K |
| 79 | PROSOMNUS INC | *W EXP 04/20/202 | 0.01% | $11,790 | 150.0K |
| 80 | SELINA HOSPITALITY PLC | *W EXP 10/27/202 | 0.00% | $8,115 | 101.4K |
| 81 | EUCRATES BIOMEDICAL ACQU COR | *W EXP 10/23/202 | 0.00% | $7,413 | 133.3K |
| 82 | SRZNWSURROZEN INC | *W EXP 08/01/203 | 0.00% | $7,023 | 82.2K |
| 83 | RELATIVITY ACQUISITION CORP | *W EXP 12/15/202 | 0.00% | $3,010 | 100.0K |
| 84 | TCBWFTC BIOPHARM HOLDINGS PLC | *W EXP 02/08/202 | 0.00% | $1,684 | 18.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $42M | 19 | May 1, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $25M | 18 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $628,262 | 1 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $42M | 24 | May 13, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2024 | $353M | 67 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $340M | 79 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $245M | 68 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $253M | 72 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $147M | 66 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $192M | 72 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 68 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 91 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $197M | 94 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $273M | 134 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $250M | 127 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $299M | 118 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $363M | 133 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $381M | 124 | Nov 17, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2021 | $431M | 135 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $360M | 124 | May 6, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $266M | 98 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.